Navigation Links
Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
Date:8/21/2008

SAN DIEGO, Aug. 21 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has authorized a Phase 1 study evaluating RDEA594 in normal healthy volunteers. RDEA594 is the Company's lead product candidate for the treatment of gout.

"Regulatory clearance for us to proceed with our Phase 1 study of RDEA594, within six months from designation as a clinical candidate is a testament to the efficiency of our development organization, and the importance we place on our gout program -- a program we intend to expand with second-generation compounds from our exciting ongoing research in this area," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "Earlier this quarter, we initiated a Phase 2a proof-of-concept study of RDEA806, a prodrug of RDEA594, which should allow us to provide an early confirmation of RDEA594's activity in the target population of patients with gout."

This Phase 1, randomized, double-blind, placebo-controlled trial will evaluate the safety, tolerability, pharmacokinetics and uric acid lowering effects of single ascending oral doses of RDEA594 in healthy adult male volunteers.

About Gout

An estimated 3-5 million people in the United States, and approximately 5 million people in the European Union, suffer from gout, which is the most common form of inflammatory arthritis in men over 40. Gout, also known as metabolic arthritis, is a painful and debilitating disease caused by abnormally elevated levels of uric acid in the blood stream. These abnormally elevated levels lead to the deposition of uric acid crystals in and around the connective tissue of the joints and in the kid
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Following a ... Committee that moved H.R. 284, the Medicare DMEPOS ... American Association for Homecare (AAHomecare) released a statement ... action to pass the legislation. "Today,s ... the House Ways and Means Committee is a ...
(Date:2/27/2015)... -- Securities lawyers at Dunnam & Dunnam ... SLXP ) in connection with a buyout ... encouraged to contact attorney Hamilton Lindley by clicking ... the shareholder value of the transaction. Under terms of ... per share in cash. At least one analyst has ...
(Date:2/27/2015)... HOUSTON, TX , Feb. 27, 2015 /PRNewswire/ - ESSA ... Bloom Burton & Co. Ltd. ("Bloom Burton") today announced ... "Lock-Up") 2,353,130 common shares of the Company ("Common Shares") ... the Lock-Up. Of the Common Shares released from the ... release from the Lock-Up while the remainder will be ...
Breaking Medicine Technology:Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4
... Sleep, the West Coast,s largest and fastest growing independent ... sleep clinic in Oakland, California.  Located one block from ... open for business. Services include sleep physician consultations, diagnostic ... other therapies for patients diagnosed with Obstructive Sleep Apnea ...
... Nov. 14, 2011 NeuroCog Trials, Inc. and Advance ... recordings of neurocognitive testing in a large international clinical ... errors in test administration and scoring.  This video recording ... accurate, unbiased assessment of neuropsychological effects of new drugs. ...
Cached Medicine Technology:Bay Sleep Clinic Continues Growth in California and Beyond 2NeuroCog Trials Captures Video Recordings of Neurocognitive Testing in a Multinational Clinical Trial 2NeuroCog Trials Captures Video Recordings of Neurocognitive Testing in a Multinational Clinical Trial 3
(Date:2/28/2015)... (PRWEB) February 28, 2015 The ... its annual awards at the International Symposium on Malignant ... be held at the Hyatt Regency Bethesda in Bethesda, ... their dedicated work and commitment to the mission to ... Year Award will be presented to Miriam Ratner. Miriam ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 A case ... testosterone lawsuits that have been filed by law firms ... second week in March, the Firm notes. , ... parties involved in the federal litigation will meet on ... related to prescription therapy treatments designed to raise levels ...
(Date:2/28/2015)... The noted Toronto plastic surgeon Dr. David Ellis ... in the January/February 2015 issue of Elevate magazine. On ... featured in an article entitled “Get the Look: Kim ... Cattrall has possibly undergone to maintain her youthful appearance ... horizontal lines or frown line creases, which can be ...
(Date:2/28/2015)... February 28, 2015 Memphis, TN: MedixSafe ... 2015, for a new security reader named Guardian ... reader is a new biometric scanner that significantly ... new features, the new biometric scanner provides fast ... administrators. , MedixSafe narcotics lockers with ...
(Date:2/27/2015)... Wireless Analytics, an award-winning ... of the founders of the wireless expense ... within their CLEAN Platform™ (Communications Lifecycle Expense Analytics) ... newly developed Bell Mobility Data Loader enables unprecedented ... carrier’s business customers. , Wireless Analytics cites customer ...
Breaking Medicine News(10 mins):Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4Health News:Dr. David Ellis Featured In Elevate Magazine 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 3
... It's no surprise that constant stress can make people sick, ... ,A study focused on 119 men and women who were ... caregivers was compared with that of 106 people of similar ... care giving. Blood tests showed that a chemical called Interleukin-6 ...
... million children worldwide die every year, most of them in ... treatments. While the childhood mortality rate in these nations has ... peaked in 1980. About half of the deaths in children ... Pakistan, Democratic Republic of Congo, and Ethiopia) and 90 percent ...
... who are bitten by animals poses little problem for doctors, ... human? ,That’s the question researchers set out to answer in ... and Neck Surgery. Their review of 10 years worth of ... believe can form a standard protocol to follow when man ...
... for preventing disease. In the future, skin ,cancer detection may ... Hattaway is a nine-year ,survivor of melanoma. He’s lucky doctors ... never found a primary, which is what you call the ... the skin. It had already gotten into my lymph system,” ...
... to prevent or delay the onset of prostate cancer, ... cancers. ,More than 18,000 men were randomized , age ... At baseline, digital rectal examination results were normal in ... more than 3.0 ng/mL. Among the 4368 men in ...
... delay the onset of prostate cancer, however, finasteride may ... 18,000 men were randomized , age 55 or older ... rectal examination results were normal in all subjects, and ... ng/mL. Among the 4368 men in the finasteride group ...
Cached Medicine News:
... a new implant. It's a new material, ... debris can be greatly reduced . The ... needs of the nickel-sensitive patient. Hardness, lubricity ... Oxinium is available in our two already ...
... anatomic knee system was ... minimize polyethylene wear between ... minimize contact stress associated ... achieve a well balanced ...
Simplified Design-Based on 15 Years of Experience...
... of more than a decade of in-vivo ... a comprehensive study of knee kinematics through ... insert retrieval analysis.,As a result of this ... motion patterns in total knees, the 3DKnee ...
Medicine Products: